Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim outlines plans for obesity therapies

Boehringer Ingelheim outlines plans for obesity therapies

13th August 2013

Boehringer Ingelheim has shone a spotlight on its plans to enter the growing obesity market by adapting its established expertise in the field of metabolic diseases.

Speaking at a recent research and development conference in London, Dr Sanjay Patel – global clinical development leader for diabetes at Boehringer Ingelheim – said this move will represent an evolution of its current focus on diabetes, reports PMLiVE.

The firm has established a foothold in the diabetes market thanks to its alliance with Lilly, which has resulted in the creation of products such as Trajenta and empagliflozin.

Its focus is now being expanded to cover some of the complications and risk factors of diabetes, such as being overweight, with research ongoing into ways of inhibiting the 11 beta-HSD1 enzyme, which is affected when people put on weight and can cause metabolic changes.

Dr Patel said: "We actually see benefits in preclinical and early clinical data that we could potentially help patients improve glucose control and control their weight through this inhibition."

This comes after Boehringer Ingelheim and Lilly commenced a new Trajenta study last week to assess cardiovascular and renal outcomes associated with the drug.ADNFCR-8000103-ID-801624163-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.